Opportunities
Active & Upcoming Solicitations
Closed Solicitations
| RPP # | Topic | Description | Submission Due Date |
|---|---|---|---|
| RFI Path(SM) | Request for Information: AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses | The purpose of this Request for Information (RFI) is to conduct market research to identify organizations with capabilities in artificial intelligence (AI) for application in the discovery and advancement of broad-spectrum, small-molecule therapeutics targeting filoviruses (e.g., Ebola virus (EBOV), Sudan virus (SUDV), Marburg virus (MARV)). | 17 June 2026 1pm EDT |
| RFI: Protection Before Day 1 | Request for Information: Protection Before Day One Vaccine: Advancing Broadly Protective Seasonal Influenza Vaccines with Pandemic Coverage | The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in identifying and understanding the development maturity of Day One influenza vaccine candidates and associated enabling technologies. This RFI seeks information on vaccine candidates and enabling approaches intended to function as Day One influenza vaccines, defined as:
| 15 July 2026 by 1pm EDT |
| Coming Soon | New Vaccine Platforms (NVP) | The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing. | TBD |
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| RPP-26-12-ARDS (4/28/2026) | Host-Directed Therapeutics for the Prevention of Progression to ARDS | 5/26/2026 |
| RPP-26-10-RAPID (4/15/2026) | Rapid Antibody Production for Immunoassay Diagnostics (RAPID) | 5/18/2026 |
| RFI: NMJ MPS Plarforms for BoNT Potency Assay (4/20/2026) | Request for Information: Neuromuscular Junction (NMJ) Micro-Physiological Systems for Botulinum Neurotoxin (BoNT) Potency Measurement and Medical Countermeasures Evaluation | 5/11/2026 |
| Request for Information: PreventARDS (4/1/2026) | Host Directed Therapeutics for the Prevention of Progression to ARDS | 4/15/2026 |
| RPP-26-07-ASSURE (11/14/2025) | Assay Development for Superior Understanding of Response and Efficacy (ASSURE) | 2/24/2026 |
| New Vaccine Platforms Request for Information (11/26/2025) | New Vaccine Platforms | 1/30/2026 |
| Rapid Antibody Production for Immunoassay Diagnostics (RAPID) Request for Information (10/31/2025) | Rapid Antibody Production | 12/4/2025 |
| RPP-26-09-AgDx (10/23/2025) | Agnostic Diagnostics | 11/20/2025 |
RPP-25-06-DxR2 | Biothreat Diagnostic Rapid Response | 8/4/2025 |
| RPP-24-07-CentralIEIDLab (5/7/2025) | Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services | 5/30/2025 |
| RPP-24-08-mRNALongTerm (08/30/2024) | Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability | 2/28/2025 |
| RPP-24-02-OralVx (09/09/2024) | NextGen Oral Formulation Vaccines for COVID-19 | 11/15/2024 |
| RPP-24-02-ODM (08/13/2024) | On-Demand Manufacturing | 9/25/2024 |
| RPP-24-03-SmMol (08/05/2024) | COVID-19 Small Molecule Therapeutics for PrEP | 9/20/2024 |
| RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | 5/17/2024 |
| RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
| RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 4/19/2024 |
| RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 3/27/2024 |
| RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 |
| RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 3/20/2024 |
| RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 1/19/2024 |
| RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 1/19/2024 |
| RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 1/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |